BOSTON--(BUSINESS WIRE)--Invetx Inc., a pioneer in protein-based therapeutics for animal health, announced today that it has agreed to be acquired by Dechra Pharmaceuticals Limited (Dechra), a global specialist veterinary pharmaceuticals business, for up to $520 million in total consideration on a cash-free and debt-free basis.

波士顿--（商业新闻短讯）--动物健康蛋白质疗法的先驱Invetx Inc.今天宣布，它已同意被全球专业兽药企业Dechra Pharmaceuticals Limited（Dechra）收购，总对价高达5.2亿美元，无现金和无债务。

The acquisition remains subject to antitrust approval and other customary closing conditions..

此次收购仍需获得反托拉斯批准和其他惯例成交条件。。

“We are thrilled to be joining forces with Dechra Pharmaceuticals, a global leader in animal health. Our pipeline of monoclonal antibody therapeutics for chronic, serious diseases in cats and dogs is highly complementary to Dechra’s broad portfolio of speciality therapeutics for companion animals and accelerates Dechra’s differentiated position in the veterinary health industry,” said Juergen Horn, Dr.med.vet., Ph.D., chief executive officer and co-founder, Invetx..

兽医Juergen Horn博士说：“我们很高兴能与动物健康领域的全球领导者Dechra Pharmaceuticals携手合作。我们针对猫和狗的慢性严重疾病的单克隆抗体治疗产品线与Dechra针对伴侣动物的广泛专业治疗产品组合高度互补，并加速了Dechra在兽医健康行业的差异化地位。”。，Invetx首席执行官兼联合创始人，博士。。

In addition to the Invetx pipeline, Dechra will gain access to the company’s species-specific, half-life extension platform, which extends duration of drug activity and enables longer intervals between treatment, offering greater convenience and improved compliance for veterinarians, owners and their pets..

除Invetx管道外，Dechra还将获得该公司针对特定物种的半衰期延长平台，该平台延长了药物活动的持续时间，延长了治疗间隔，为兽医、主人及其宠物提供了更大的便利和更好的依从性。。

“Invetx’s ability to develop veterinary biotherapeutics with an extended duration of effect and longer inter-dosing intervals represents a significant innovation in animal health,” said Jesper Nordengaard, chief executive officer of Dechra. “The Invetx products in development have significant potential and will deepen our expertise in core therapeutic areas such as atopic dermatitis and osteoarthritis, allowing for synergistic product development, sales and marketing, and education efforts in the future.”.

Dechra首席执行官Jesper Nordengaard说：“Invetx开发兽医生物治疗药物的能力，具有延长的作用持续时间和更长的给药间隔，代表了动物健康方面的重大创新。”。“正在开发的Invetx产品具有巨大潜力，将加深我们在特应性皮炎和骨关节炎等核心治疗领域的专业知识，从而在未来实现协同产品开发、销售和营销以及教育工作。”。

The half-life extension technology is part of Invetx’s overall integrated platform, which includes state-of-the-art antibody discovery technology, optimization, development and manufacturing for best-in-class and differentiated veterinary biotherapeutics.

半衰期延长技术是Invetx整体集成平台的一部分，该平台包括最先进的抗体发现技术，针对一流和差异化兽医生物治疗药物的优化，开发和制造。

As a start-up company, Invetx was initially incubated by Anterra Capital, a Boston- and Amsterdam-based venture capital firm focused on investments in animal health and agrifood innovation. Phil Austin, managing partner and co-founder of Anterra Capital, stated “The exit of Invetx is an exceptional outcome not only for the stakeholders in the company but also for the broader start-up community and the animal health industry.

作为一家初创公司，Invetx最初由Anterra Capital孵化，Anterra Capital是一家总部位于波士顿和阿姆斯特丹的风险投资公司，专注于动物健康和农产品创新投资。Anterra Capital的管理合伙人兼联合创始人菲尔·奥斯汀（Phil Austin）表示：“Invetx的退出不仅对公司的利益相关者，而且对更广泛的创业社区和动物保健行业都是一个特殊的结果。

Invetx is a great example of how start-ups can drive innovation in this industry. We are excited to see the Invetx products come to market and support Dechra in its ambitious growth plans.”.

Invetx是一个很好的例子，说明了初创企业如何推动该行业的创新。我们很高兴看到Invetx产品上市，并支持Dechra的雄心勃勃的增长计划。”。

BofA Securities, Inc. is acting as exclusive financial advisor to Invetx and Latham & Watkins LLP is acting as legal advisor.

美国银行证券公司（BofaSecurities，Inc.）担任Invetx的独家财务顾问，Latham&Watkins LLP担任法律顾问。

About Invetx

关于Invetx

Invetx is a pioneer in creating novel, protein-based animal health therapeutics to transform standards of care in veterinary medicine. The company leverages a best-in-class, fully integrated biotechnology platform for the discovery, development, and manufacturing of veterinary monoclonal antibodies, and is developing a diverse product pipeline addressing chronic and severe diseases in companion animals..

Invetx是创建新型基于蛋白质的动物健康疗法以改变兽医护理标准的先驱。该公司利用一流的、完全集成的生物技术平台来发现、开发和制造兽医单克隆抗体，并正在开发一条多样化的产品线，以解决伴侣动物的慢性和严重疾病。。

Invetx has raised $86 million since 2018, including investors F-Prime Capital, Novo Holdings, GV, Eight Roads, Anterra Capital, Casdin Capital and funds managed by Tekla Capital Management, LLC. Strategic investment partners include AbCellera, a global technology company specializing in antibody discovery located in Vancouver, BC, and WuXi Biologics, a global company with leading biologics technology platforms..

自2018年以来，Invetx已筹集了8600万美元，其中包括投资者F-Prime Capital、Novo Holdings、GV、Eight Roads、Anterra Capital、Casdin Capital和Tekla Capital Management，LLC管理的基金。战略投资伙伴包括位于不列颠哥伦比亚省温哥华的专门从事抗体发现的全球技术公司AbCellera和拥有领先生物制剂技术平台的全球公司无锡生物制品公司。。

Invetx is headquartered in Boston, Massachusetts. For more information, see www.invetx.com.

Invetx总部位于马萨诸塞州波士顿。有关更多信息，请访问www.invetx.com。

About Dechra

关于德克拉

Dechra is a global specialist veterinary pharmaceuticals and related products business. Dechra’s expertise is in the development, manufacture, and sales and marketing of high quality products, exclusively for veterinarians, to support the sustainable improvement of animal health and welfare worldwide.

Dechra是一家全球专业兽医药品和相关产品企业。德克拉的专业知识是专门为兽医开发、制造、销售和营销高质量产品，以支持全球动物健康和福利的可持续改善。

For more information, please visit: www.dechra.com.

有关更多信息，请访问：www.dechra.com。